Navigation Links
Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R)
Date:1/23/2008

Fund's Third Investment in Vaccine to Prevent Rotavirus

NEW YORK, Jan. 23 /PRNewswire/ -- Paul Capital Healthcare today announced that it has purchased a royalty interest in Rotarix(R) from Cincinnati Children's Hospital Medical Center. Rotarix(R) is an oral vaccine developed to prevent rotavirus infection, a contagious viral disease that causes diarrhea and dehydration in infants and young children. The product is marketed by GlaxoSmithKline (GSK) and has been approved in over 100 countries including all of Europe, most of Latin America, and much of Asia, Africa and the Middle East.

Under the terms of this agreement, Paul Capital Healthcare acquired all royalties on worldwide sales of Rotarix(R) from Cincinnati Children's. This is the third investment that the Fund has completed related to Rotarix(R) royalties. In November 2005, Paul Capital Healthcare acquired an interest in Rotarix(R) from three inventors at Cincinnati Children's; and in May 2005 acquired a portion of AVANT Immunotherapeutics' total royalties on Rotarix(R).

"Rotavirus is a serious condition that impacts millions of infants and young children worldwide, leading to fatalities in many cases. We believe that Rotarix(R) addresses a critical global health need and are confident in the long-term viability of the product," said Dr. Walter Flamenbaum, Partner, Paul Capital Healthcare.

Rotarix(R) was invented and initially developed by researchers now at Cincinnati Children's. In 1995, AVANT in-licensed the Rotarix(R) technology from Cincinnati Children's. GSK subsequently licensed the product from AVANT in 1999. According to GSK, rotavirus infects virtually every child worldwide by age five and is the leading cause of severe acute gastroenteritis in infants and young children worldwide. Severe diarrhea and dehydration occurs in infants as young as three months of age with peak incidence between six months and two years.

About Paul Capital Partners and Paul Capital Healthcare

Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms that include healthcare direct investments (including royalty and revenue interests in healthcare products), Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London and Toronto. Paul Capital Healthcare is one of the largest dedicated healthcare funds globally, with $1.8 billion in equity capital commitments and debt facilities under management. Paul Capital Healthcare has invested more than $875 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. For more information, visit http://www.paulcapitalhealthcare.com.

Contacts:

Fern Lazar

Lazar Partners

212-867-1765

flazar@lazarpartners.com


'/>"/>
SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
4. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
7. Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA
8. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
9. BD to Present at Investor Healthcare Conferences
10. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
11. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
(Date:5/3/2016)... Global Insulin Needles Industry ... key companies and supported with 272 tables and ... on the current state of the Insulin Needles ... including definitions, classifications, applications and industry chain structure. ... the international market including development history, competitive landscape ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC ... Stong is double board certified and the only facial plastic surgeon in Atlanta to ... Non-surgical therapies such as stem cells can be used to provide stabilization to hair ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week 2016, ... the United States to thank a nurse who's made a difference in their life. ... the American Red Cross of San Diego/Imperial Counties (up to $10,000) every time someone ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... PLAINSBORO, N.J. (PRWEB) , ... May 05, 2016 , ... ... on patients with cancer, today announced a new collaboration with Imerman Angels ... of cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to ...
Breaking Medicine News(10 mins):